**Core tip:** The high prevalence of obesity and the metabolic syndrome suggests that many patients with liver disease of varying etiologies will have co-existent non-alcoholic fatty liver disease. Our model of co-toxic liver disease incorporates increased hepatic iron in combination with steatosis and was associated with necroinflammation and early hepatic fibrosis. Because of the beneficial effect of combination therapy, we believe vitamin E and curcumin should be investigated in other animal models of non-alcoholic steatohepatitis. Should beneficial effects be demonstrated, combination treatment with the development of appropriate dosing strategies could be rapidly moved to human studies allowing for an effective treatment strategy.

INTRODUCTION
============

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries\[[@B1]\] and encompasses a range of hepatic pathologies from simple steatosis to the more aggressive non-alcoholic steatohepatitis (NASH)\[[@B2]\]. Homozygosity for the C282Y mutation in the *HFE* gene is the most common cause of hereditary hemochromatosis (HH)\[[@B3]\]. Steatosis is common in patients with HH\[[@B4]\] and is associated with increased hepatic fibrosis; conversely, heterozygosity for the C282Y mutation in *HFE* is common in patients with NAFLD\[[@B5]\]. Even mild increases in hepatic iron concentration (HIC) may play an important role in the transition from simple steatosis to NASH as *Hfe^-/-^* mice fed a high calorie diet develop NASH, impaired anti-oxidant activity and accelerated liver injury\[[@B6]\]. This relationship between HFE, altered iron metabolism and the development of NAFLD could be the target for therapeutic strategies that may attenuate disease progression in NASH. Curcumin, the yellow pigment of the plant *Curcuma longa* (turmeric), has potent antioxidant and chemo preventative effects\[[@B7]\]. Curcumin treatment produces beneficial effects in many animal models of liver diseases\[[@B8],[@B9]\]. Curcumin ameliorates the early stages of experimental steatohepatitis and limits the development and progression of fibrosis in mice fed a methionine choline deficient diet\[[@B10],[@B11]\]. In addition, a recent randomised controlled trial of curcumin in fatty liver patients demonstrated a reduction in NASH features\[[@B12]\]. The anti-oxidant, vitamin E has been shown to be beneficial in animal models of liver disease and in subjects with NASH\[[@B13]-[@B15]\].

Curcumin and vitamin E have been used with therapeutic benefit in experimental models of NASH\[[@B10],[@B11],[@B14]\]. To date, these agents have mostly been used at the initiation of injury which does not validate their utility in NASH in the usual clinical situation of already established injury and ongoing exposure to excess calorie intake. We hypothesized that these two agents may have synergistic activity in attenuating disease progression in NASH. Thus, in the present study, we investigated combination use of curcumin and vitamin E in the treatment of *Hfe^-/-^* mice with established liver injury induced by a high-fat, high-carbohydrate diet, and with ongoing exposure to the diet. Our results show that combination treatment of curcumin and vitamin E decreased liver injury and hepatic steatosis suggesting that this treatment may be of therapeutic value in NAFLD.

MATERIALS AND METHODS
=====================

Animals
-------

All animals received humane care under the guidelines and approval of the QIMR Berghofer Medical Research Institute and The University of Queensland Animal Ethics Committees. Eight-week-old male *Hfe^-/-^* mice (on a C57BL/6J background)\[[@B16]\], were fed a high calorie diet (HCD) (SF03-020, Speciality Feeds, Glen Forrest, WA, Australia) (*n* = 34) for a period of 10 wk. The mice were then randomly assigned (*n* = 7-9 per group) to receive either HCD alone, or HCD and 1 mg/g curcumin (Curcumin C^3^ complex, Sabinsa Corporation, Sydney, NSW, Australia), HCD and 1.5 mg/g vitamin E or HCD and a combination of 1 mg/g curcumin and 1.5 mg/g vitamin E for a further 10 wk (Specialty Feeds). The fat composition of the HCD by weight was 150 mg/g saturated fat, 20 mg/g polyunsaturated and 60 mg/g monounsaturated fat, derived from a predominant mixture of cocoa butter (50 mg/g), partially hydrogenated vegetable oil (131 mg/g) and canola oil (50 mg/g) with added cholesterol (1.9 mg/g). Animals were allowed *ad libitum* access to diets and drinking water. After 20 wk of dietary treatment, animals were sacrificed under anaesthesia following cardiac puncture for blood collection. The livers were removed and portions were snap-frozen in liquid nitrogen and stored at -80 °C prior to analysis. Separate portions were collected for histology or dried for the determination of hepatic iron concentration (HIC). Epididymal fat pads were weighed and stored at -80 °C.

Histopathological analysis
--------------------------

Liver samples were fixed in 40 g/L neutral-buffered formalin, embedded in paraffin, sectioned and stained with haematoxylin-eosin (H and E). Histological parameters were staged and graded according to accepted criteria by a specialist liver pathologist in a blinded fashion\[[@B17]\]. Steatosis was graded according to the percentage of steatotic hepatocytes (grade 0, \< 5% affected; grade 1, 5%-33% affected; grade 2, 34%-66% affected; and grade 3, \> 66% affected). Lobular inflammatory activity was scored based on the number of inflammatory foci per 200x field (0, none; 1, \< 2 seen; 2, 2-4 seen; and 3, \> 4 seen) and ballooning was scored based on the degree of hepatocyte ballooning (0, none; 1, few; and 2, many). Activity was also scored using NAFLD activity score (NAS) established by the NASH Clinical Research Network (CRN), which is an unweighted sum of scores for steatosis (0-3), lobular inflammation (0-3) and ballooning (0-2)\[[@B17]\].

Fibrosis stage was assessed following Picro Sirius Red staining for collagen according to the criteria established by Brunt et al\[[@B18]\].

Serum biochemistry and hepatic iron concentration
-------------------------------------------------

Serum concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured on a Cobas Integra 400 Chemistry Automated Analyser as per manufacturer's instructions (Roche Diagnostics, Castle Hill, NSW, Australia). HIC was measured as previously described\[[@B6],[@B19]\].

Hepatic antioxidant enzyme assay
--------------------------------

Total cellular glutathione peroxidase (GPx), reduced (GSH) and oxidized glutathione (GSSG), catalase and mitochondrial manganese superoxide dismutase (MnSOD) activities were measured on homogenized liver tissue using commercial assay kits as per manufacturer's instructions (Cayman Chemical, Ann Arbor, MI, United States).

RNA extraction and quantitative real-time polymerase chain reaction
-------------------------------------------------------------------

Total RNA was extracted using TRIzol reagent (Invitrogen, Mount Waverley, Victoria, Australia), subjected to deoxyribonuclease I digestion and transcribed into cDNA using Superscript III according to the manufacturer's instructions (Invitrogen). Quantitative gene expression was performed by real-time polymerase chain reaction (RT-PCR) (ViiA^TM^ 7, Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, United States) using Quantifast SYBR green as per manufacturer's conditions (Qiagen, Chadstone Centre, VIC, Australia). The expression of individual genes were normalised to the geometric mean of three house-keeper genes: Basic transcription factor 3 (*Btf-3*), Glyceraldehyde-3-phosphate dehydrogenase (*Gapdh)* and β2-microglobulin (β*2-m*). Mouse primer sequences for genes investigated are shown in Supplementary Table [1](#T1){ref-type="table"}.

###### 

Percent steatosis, lobular and non-alcoholic fatty liver disease activity score were reduced due to combination therapy

                        **HCD (*n* = 9)**   **HCD + Cu (*n* = 9)**   **HCD + VE (*n* = 7)**   **HCD + Cu + VE (*n* = 9)**
  --------------------- ------------------- ------------------------ ------------------------ --------------------------------------------
  Histology diagnosis   NASH (9)            Steatosis (2)/NASH (7)   Steatosis (2)/NASH (5)   Steatosis (4)/NASH (5)
  Steatosis grade       3 (3-3)             3 (2-3)                  3 (2-3)                  3 (2-3)
  \% steatosis          95 (80-100)         80 (40-100)              95 (70-100)              75 (40-95)[a](#T1FN1){ref-type="table-fn"}
  Lobular score         2 (1-2)             2 (1-3)                  1 (0-2)                  1 (0-3)
  Ballooning            2 (1-2)             2 (1-2)                  1 (1-2)                  1 (0-2)
  NAS score             6 (5-7)             6 (4-8)                  6 (4-6)                  5 (3-8)
  Fibrosis stage        1a (0-1a)           0 (0-1a)                 0 (0-1a)                 0 (0-1a)

Values are expressed as the median (range).

*P* \< 0.05 *vs* HCD alone, Kruskal-Wallis ANOVA. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E; NAS: Non-alcoholic fatty liver disease activity score.

Western blot and densitometry analysis
--------------------------------------

Protein extracts (30 µg) from liver were electrophoresed in sodium dodecyl sulphate-10% polyacrylamide gel for 30 min at 100 V and blotted onto polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, United States) as previously described\[[@B6]\]. Membranes were immunostained with primary antibodies for ACOX (Abcam, Cambridge, MA, United States) and mitoNEET (Proteintech, Chicago, IL, United States). Signals were detected using standard chemiluminescence (Supersignal West Femto, ThermoFisher Scientific, Scoresby, Victoria, Australia) on an Image Station 4000MM Pro and quantified using Carestream Molecular Imaging software (Carestream Australia, East Melbourne, Victoria, Australia).

Statistical analysis
--------------------

Statistical analysis was performed using IBM SPSS Statistics 22 (IBM, Armonk, NY, United States). Non-parametric tests were used to evaluate differences between groups, and data are depicted using box and whisker plots showing median, minimum and maximum values. A Kruskal-Wallis test with Dunn's correction for multiple comparisons was performed to compare intervention groups. A cut-off *P* value of 0.05 was used to determine significance. Statistical review of the manuscript was performed by a biomedical statistician.

RESULTS
=======

Serum transaminase concentrations are decreased by curcumin and vitamin E combination therapy
---------------------------------------------------------------------------------------------

Total body weight and liver weight were not altered by dietary treatment in *Hfe^-/-^* mice (Figure [1A](#F1){ref-type="fig"}). Epididymal fat pad weight was significantly reduced in the combination treatment group compared to curcumin alone (*P* \< 0.02, Figure [1A](#F1){ref-type="fig"}).

![Epididymal fat pad weights and serum transaminase concentrations are decreased by curcumin and vitamin E combination therapy. *Hfe^-/-^* mice were fed HCD for 10 wk then HCD + Cu, HCD + VE or HCD + Cu + VE for a further 10 wk (*n* = 7-9). A: Body, liver and epididymal fat pad weights were determined. B: Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations were determined on final cardiac bleeds. Following sacrifice, a dried liver segment was digested to determine hepatic iron concentration (HIC). Data are depicted using box and whisker plots showing median, minimum and maximum values. Statistical significance was tested using Kruskal-Wallis test with Dunn's correction for multiple comparisons, ^a^*P* ≤ 0.05. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E.](WJGP-8-67-g001){#F1}

Serum ALT concentrations were significantly reduced by combination treatment compared to HCD alone (*P* = 0.02, Figure [1B](#F1){ref-type="fig"}). AST concentrations were not significantly different across groups (*P* = 0.12). There was no significant effect of dietary treatment on HIC (*P* \< 0.30, Figure [1B](#F1){ref-type="fig"}).

Attenuation of severe steatosis and lobular inflammation by curcumin and vitamin E combination therapy
------------------------------------------------------------------------------------------------------

*Hfe^-/-^* HCD-fed mice developed moderate to severe steatosis with hepatocyte ballooning and inflammatory cell infiltration present in 100% of mice meeting the criteria for steatohepatitis (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}). Combination treatment with curcumin and vitamin E reduced the presence of NASH to only 55% of mice. Combination treatment also significantly reduced percent steatosis compared with HCD alone (*P* = 0.03). Lobular inflammatory score and NAS score were also reduced in combination treated *Hfe^-/-^* mice (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}). Treatment with either curcumin or vitamin E alone had minimal effects on hepatic histology (Figure [2A](#F2){ref-type="fig"}).

![Steatosis is attenuated by curcumin and vitamin E combination therapy while the expression of fibrotic and inflammatory genes are not significantly altered. A: Representative liver paraffin-embedded sections stained with hematoxylin and eosin (H and E) (original magnification × 20). a: *Hfe^-/^*^-^ mice (n = 7-9 per group) fed HCD (20 wk); b: HCD (10 wk) then HCD + 1% curcumin (10 wk); c: HCD (10 wk) then HCD + 1.5% vitamin E (10 wk); d: HCD (10 wk) then HCD + 1% curcumin + 1.5% vitamin E (10 wk). qRT-PCR was used to determine expression levels of hepatic (B) fibrogenic genes: α1(I)-procollagen (Col1a1); Transforming growth factor β (TGF-β); Tissue inhibitor of metalloproteinase 1 (Timp1); C: Hepatic inflammatory genes: monocyte chemoattractant protein-1 (Mcp-1); orosmucoid 1 (Orm1) and serum amyloid A 1 (Saa1). Data are depicted using box and whisker plots showing median, minimum and maximum values. Statistical significance was tested using Kruskal-Wallis test with Dunn's correction for multiple comparisons. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E.](WJGP-8-67-g002){#F2}

Centrilobular (stage 1) fibrosis (as detected by Sirius red staining) was observed in 7/9 *Hfe^-/-^* mice fed the HCD and only in 3/9 combination treated mice, as evidenced by reduced staining (data not shown). However, hepatic α~1~(I)-procollagen (*Col1a1*) mRNA, transforming growth factor β~1~ (*Tgf*β*1*) and tissue inhibitor of metalloproteinase 1 (*Timp1*) gene expression were not significantly altered by dietary treatment (*P* = 0.05, *P* = 0.40 and *P* = 0.26 respectively, Figure [2B](#F2){ref-type="fig"}). Gene expression of monocyte chemoattractant protein-1 (*Mcp-1*) and two acute phase reactants, orosomucoid 1 (*Orm-1*) and serum amyloid A1 (*Saa1*) were not significantly altered by combination treatment when compared to HCD or monotherapy (*P* = 0.08, *P* = 0.07 and *P* = 0.17 respectively, Figure [2C](#F2){ref-type="fig"}).

Enhanced gene expression of fatty acid oxidation pathways with curcumin and vitamin E combination therapy
---------------------------------------------------------------------------------------------------------

Hepatic adiponectin receptor 2 (*AdipoR2*) mRNA expression was significantly increased in vitamin E and combination treatment groups compared to HCD alone (*P* = 0.02 and *P* \< 0.01, respectively).

Downstream of *AdipoR2*, peroxisome proliferator-activated receptor α (*Ppar*α) mRNA expression was significantly increased in combination treated *Hfe^-/-^* mice compared to HCD alone and curcumin alone (*P* \< 0.012 and *P* = 0.01, respectively, Figure [3A](#F3){ref-type="fig"}). Carnitine palmitoyl transferase 1A (*Cpt1a*) expression was also increased due to dietary treatments where vitamin E and combination treatment significantly increased *Cpt1a* expression in *Hfe^-/-^* mice compared to HCD alone (*P* = 0.05 and *P* \< 0.01, respectively, Figure [3A](#F3){ref-type="fig"}). In addition, combination therapy increased *Cpt1a* expression above curcumin treatment alone *(P \<* 0.01, Figure [3A](#F3){ref-type="fig"}*)*. The expression of acyl-coenzymeA oxidase 1 (ACOX1) protein, the first enzyme in the β-oxidation pathway, was significantly different following dietary intervention. Combination treatment up-regulated ACOX1 expression compared with HCD alone (*P* \< 0.01, Figure [3B](#F3){ref-type="fig"}). These results suggest an increase in lipid metabolism by β-oxidation which has been altered by long-term HCD feeding.

![Altered lipid signalling following high calorie diet feeding is abrogated by curcumin and vitamin E combination therapy. qRT-PCR was used to determine expression levels of hepatic fatty acid oxidation genes in *Hfe^-/-^* mice fed HCD, HCD + Cu, HCD + VE or HCD + Cu + VE. A: Adiponectin receptor 2 (AdipoR2) mRNA; peroxisome proliferator-activated receptor α (PPARα) and carnitine palmitoyl transferase 1A (Cpt1a) mRNA; B: Western blotting and densitometry analysis was performed to determine levels of acyl-coenzymeA oxidase 1 (ACOX) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Data are depicted using box and whisker plots showing median, minimum and maximum values. Statistical significance was tested using Kruskal-Wallis test with Dunn's correction for multiple comparisons, ^a^*P* ≤ 0.05, ^b^*P* ≤ 0.01, ^e^*P* ≤ 0.001. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E.](WJGP-8-67-g003){#F3}

Effects on hepatic antioxidant enzyme activities and mitochondrial function
---------------------------------------------------------------------------

Neither glutathione peroxidase activity (GPx) nor hepatic mitochondrial manganese superoxide dismutase (MnSOD) activity were significantly altered by dietary treatments (*P* = 0.4 and *P* = 0.80, respectively, Figure [4A](#F4){ref-type="fig"}). However both curcumin and combination treatment increased catalase when compared to HCD alone (*P* = 0.01 and *P* \< 0.01, respectively, Figure [4A](#F4){ref-type="fig"}).

![Curcumin and vitamin E treatments increase hepatic antioxidant enzyme activities and increase mitochondrial biogenesis. Hepatic tissue from Hfe-/- mice fed HCD for 10 wk then HCD + Cu, HCD + VE or HCD + Cu + VE for a further 10 wk (*n* = 7-9) was analysed for (A) glutathione peroxidase (GPx) activity, catalase activity and mitochondrial superoxide dismutase (MnSOD) activity. qRT-PCR was used to determine expression levels of hepatic (B) nuclear transcription factor 1 (Nrf-1) and transcription factor B2 mitochondrial (TfB2M). C: Western blotting and densitometry analysis was performed to determine levels of hepatic mitoNEET and glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Data are depicted using box and whisker plots showing median, minimum and maximum values. Statistical significance was tested using Kruskal-Wallis test with Dunn's correction for multiple comparisons, ^a^*P* ≤ 0.05, ^b^*P* ≤ 0.01, ^e^*P* ≤ 0.001. HCD: High calorie diet; Cu: Curcumin; VE: Vitamin E.](WJGP-8-67-g004){#F4}

We have previously shown mitochondrial dysfunction in *Hfe^-/-^* mice fed a HCD\[[@B6]\], therefore we then investigated if combination treatment could correct this defect. Indeed, nuclear transcription factor 1 (*Nrf-1)* mRNA expression was significantly altered by dietary treatments in *Hfe^-/-^* mice (Figure [4B](#F4){ref-type="fig"}), where vitamin E and combination treatment significantly increased expression compared to HCD alone (*P* = 0.01 and *P* \< 0.01, respectively). Likewise, transcription factor B2 mitochondrial (*TfB2M*) mRNA was significantly increased in *Hfe^-/-^* mice treated with vitamin E and combination treatment compared to HCD (*P* \< 0.01 and *P* \< 0.01, respectively, Figure [4B](#F4){ref-type="fig"}). These results suggest an up-regulation in mitochondrial biogenesis due to vitamin E and combination treatment. Interestingly, mitoNEET, a protein that is a driving force behind mitochondrial biogenesis\[[@B20]\], was not significantly different in combination treated animals compared with HCD alone (Figure [4C](#F4){ref-type="fig"}).

DISCUSSION
==========

In this study we demonstrated that the combination of curcumin and vitamin E therapy attenuated steatosis and lobular inflammation in *Hfe^-/-^* mice even with ongoing feeding of a HCD. *Hfe*^-/-^ mice fed a HCD for 20 wk developed steatosis and 100% had histological features consistent with steatohepatitis and the majority of animals showed centrilobular fibrosis. Monotherapy with either vitamin E or curcumin had no effect on percent steatosis, but combination therapy reduced percent hepatic steatosis as well as lobular inflammation, ballooning degeneration and fibrosis. This implies that vitamin E and curcumin exert a synergistic effect over that provided by each individual therapy.

Our previous studies have shown that *Hfe*^-/-^ mice fed a HCD develop steatosis and the pathophysiology of this injury involves altered β-oxidation, impaired fatty acid uptake and mitochondrial dysfunction\[[@B6]\]. To assess the mechanisms through which curcumin and vitamin E may exert their beneficial effect we examined fatty acid uptake, β-oxidation and mitochondrial function in this study.

Curcumin has been reported to increase the metabolism of lipids by β-oxidation\[[@B21],[@B22]\] and this appears to be a mechanism by which combination therapy results in reduced hepatic steatosis in this study. This was evidenced by increased *AdipoR2, Ppar-*α and *Cpt1a* mRNA expression in the combination fed *Hfe^-/-^* mice; facilitating increased mitochondrial uptake of free fatty acids. *AdipoR2* has been shown to activate *Ppar-α* and fatty acid oxidation genes\[[@B23]\], and these results imply that combination therapy induced *AdipoR2* expression, resulting in the up-regulation of fatty acid oxidation pathways\[[@B24]\]. However, it is worth noting that the change in *AdipoR2 and Cpt1* expression with vitamin E monotherapy alone was similar to that achieved by combination therapy. Increased ACOX1 expression, facilitating increased β-oxidation, was also observed in combination treated animals, providing further evidence of increased fatty acid β-oxidation.

We examined defence mechanisms against oxidative stress as another potential reason for the benefits of combination therapy since both curcumin and vitamin E are potent anti-oxidants. Curcumin and combination treatment in *Hfe^-/-^* mice raised catalase activity illustrating that an up-regulation in β-oxidation was counteracted by an up-regulation of an enzyme that removes excess reactive oxygen species. These observations are consistent with other models of hepatic injury where the anti-oxidant effects of curcumin and vitamin E are mediated by altering catalase and MnSOD activity\[[@B25],[@B26]\].

Vitamin E and combination treatment increased gene expression of *Nrf-1* and *Tfb2m* which are consistent with up-regulated mitochondrial biogenesis. It has been suggested that curcumin may be similar to resveratrol in this respect through activating PPARγ coactivator 1-alpha (PGC-1α)\[[@B21],[@B22]\], a regulator of mitochondrial biogenesis\[[@B27]\]. Indeed, curcumin increases PGC-1α and *Nrf-1* gene expression *in vitro*, protecting against mitochondrial impairment induced by high free fatty acids\[[@B28]\]. A recent study in a rat model of NASH demonstrated attenuation of liver injury by curcumin which the authors suggested was Nrf-1 mediated\[[@B29]\]. Combination treatment increased *Nrf-1* and TfB2m expression in *Hfe^-/-^* mice but failed to increase the expression of mitoNEET. These results are similar to MnSOD activity where combination treatment failed to restore its activity above a HCD-induced suppression. Down-regulation of mitoNEET causes an increase in iron content into the mitochondria and decreases the mitochondria's capacity to carry out electron transport and oxidative phosphorylation\[[@B20]\], potentially increasing oxidative stress and further damaging mitochondria. Indeed, mitochondrial dysfunction is associated with insulin resistance and the development of type 2 diabetes where diminished oxidative capacity is thought to be involved in disease pathogenesis\[[@B30]\]. Taken together, these findings of our study suggest that combination treatment manages to enhance the capacity for fatty acid disposal by β-oxidation without increasing oxidative stress.

This study is limited by the use of an animal model which cannot fully replicate the pathophysiology of human NASH. The dietary model incorporated high levels of curcumin which may not be easily replicated in humans. Further studies examining dosing of curcumin and vitamin E in humans are still required. While these studies have suggested potential mechanistic pathways involved in efficacy of combination treatment, we have not fully elucidated mechanisms responsible for the synergistic effects of combination therapy over monotherapy.

The high prevalence of obesity and the metabolic syndrome suggests that many patients with liver disease of varying etiologies will have co-existent non-alcoholic fatty liver disease. Indeed contemporary clinical practice in hepatology is often characterised by the need to address multiple co-toxins in one patient. The results of the present study illustrate of the concept of co-toxic liver disease since our model incorporates increased HIC in combination with steatosis and was associated with necroinflammation and early hepatic fibrosis. Curcumin and vitamin E therapy resulted in attenuation of steatosis through increased fatty acid β-oxidation, increased catalase activity and upregulated mitochondrial biogenesis. Because of the beneficial effect of combination therapy, we believe vitamin E and curcumin should be investigated in other animal models of NASH, and could be moved rapidly into human studies if a beneficial effect is demonstrated, and if appropriate dosing strategies can be developed.
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Background
----------

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries and encompasses a range of hepatic pathologies from simple steatosis to the more aggressive non-alcoholic steatohepatitis (NASH). Homozygosity for the C282Y mutation in the *HFE* gene is the most common cause of hereditary hemochromatosis (HH). Steatosis is common in patients with HH and is associated with increased hepatic fibrosis; conversely, heterozygosity for the C282Y mutation in HFE is common in patients with NAFLD. Even mild increases in hepatic iron concentration (HIC) may play an important role in the transition from simple steatosis to NASH. Curcumin and vitamin E have been used with therapeutic benefit in experimental models of NASH, therefore this study investigated the role of curcumin and vitamin E in ameliorating injury in a model of iron overload and fatty liver.

Research frontiers
------------------

Therapies for NASH and fatty liver disease are lacking and due to the growing prevalence of fatty liver disease are increasing important for treatment of this growing number of patients.

Innovations and breakthrough
----------------------------

This study utilised combination treatment with curcumin and vitamin E which differed from previous studies which only examined monotherapy. In addition, this study examined the efficacy of treatment in established fatty liver disease, not solely at the initiation of injury.

Applications
------------

As both curcumin and vitamin E have been used clinically the authors suggest that combination treatment could be easily moved into human clinical trials.

Terminology
-----------

Non-alcoholic fatty liver disease: Encompasses a range of hepatic pathologies from simple steatosis to the more aggressive non-alcoholic steatohepatitis; Haemochromatosis: An iron-overload disease which results in hepatic iron accumulation.
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